ArticleBMC cancer2021

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.

Khanh B Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.